Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,323 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more

Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions: Aficamten (5 - 20 mg); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 57
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more

Conditions: Mitochondrial Disease
Interventions: sevoflurane; Drug
Lead sponsor: d sessler; Other
Eligibility: 12 Months to 16 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Antithrombin III Deficiency
Interventions: Recombinant human antithrombin (rhAT); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • New York, New York

Conditions: Indolent Systemic Mastocytosis
Interventions: Avapritinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more

Conditions: Metastatic Solid Tumors
Interventions: AT13387; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 4
States / cities: Tucson, Arizona • Boston, Massachusetts

Conditions: Hematologic Neoplasms
Interventions: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: tDCS Administration during MRI, Remotely-supervised Daily tDCS Administration, Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 79 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, Standard of Care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: COVID-19
Interventions: Cyclosporine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions: GCSF, meloxicam, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury
Interventions: Riluzole; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Miami, Florida • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Major Depressive Disorder With Psychotic Features
Interventions: Quetiapine, escitalopram, Sertraline, Citalopram; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions: MODI Algorithm; Device
Lead sponsor: DreaMed Diabetes; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more

Conditions: Hidradenitis Suppurativa
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: SNX281, pembrolizumab; Drug
Lead sponsor: Stingthera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 1 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer acetate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 7 more

Conditions: Pediatric Disorder, Pediatric Obesity, Primary Hypertension
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 5 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pancreatic Cancer
Interventions: Oxaliplatin, Irinotecan, 5-FU, Gemcitabine, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Lurbinectedin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Kissimmee, Florida • Tampa, Florida

Conditions: Advanced Breast Cancer
Interventions: Ribociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 26
States / cities: Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Previously Treated Non Small Cell Lung Cancer
Interventions: AZD1775, AZD1775 Placebo, Antimitotic Agent, pegfiligrastim; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more

Conditions: Rib Fractures
Interventions: hydromorphone hydrochloride, Infusion catheter placement, bupivicaine 0.25%, bupivicaine 0.5%; Drug · Procedure
Lead sponsor: Anthony Iacco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Ketosis Prone Diabetes
Interventions: Continuous Glucose Monitoring, Insulin; Device · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Search by objective public record fields.

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Anesthetic Effects in Mitochondrial Disease

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

Cyclosporine in Patients With Moderate COVID-19

Meloxicam vs Placebo for Mobilization

Safety of Riluzole in Patients With Acute Spinal Cord Injury

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity